Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
06 Februar 2024 - 2:30PM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company pioneering neuroscience to deliver first-in-class therapies
for psychiatric and neurological disorders, today announced it will
host a conference call and webcast on Tuesday, February 13, 2024,
at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report
results for its fiscal year 2024 third quarter ended December 31,
2023 and provide a corporate update.
Event: Vistagen Fiscal Year 2024 Third Quarter Corporate
Update Conference Call Date: Tuesday, February 13, 2024
Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US
Dial-in (Toll-free): 1-877-407-9716 TOLL/International
Dial-in: 1-201-493-6779 Conference ID: 13743176
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1648110&tp_key=097d964c22
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on
Tuesday, February 13, 2024. To listen to the replay, call toll-free
1-844-512-2921 within the United States or 1-412-317-6671 when
calling internationally (toll). Please use the replay access ID
number: 13743176.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company pioneering neuroscience to deliver
first-in-class therapies for psychiatric and neurological
disorders. Five of Vistagen's six clinical-stage product candidates
belong to a new class of drugs known as pherines, which have the
potential to rapidly deliver meaningful efficacy with a
differentiated safety profile. Pherines are investigational
neuroactive nasal sprays with innovative proposed mechanisms of
action that activate chemosensory neurons in the nasal passages to
impact fundamental neural circuits in the brain without the need
for systemic absorption or binding to receptors in the brain.
Vistagen’s sixth clinical-stage product candidate, AV-101, is an
investigational oral drug candidate with the potential to inhibit,
but not block, NMDA receptor activity. Vistagen is passionate about
transforming what is possible in the treatment of anxiety,
depression, and other neuroscience disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206380065/en/
Investors Mark A. McPartland (650) 577-3606
markmcp@vistagen.com
Media Caren Scannell (650) 577-3601
cscannell@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024